Silo Pharma Secures Canadian Patent for PTSD Treatment SPC-15

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical and cryptocurrency treasury company, has received a Notice of Allowance from the Canadian Intellectual Property Office (CIPO) for a patent application covering its lead asset, SPC-15, an intranasal 5-HT4 receptor agonist designed to treat post-traumatic stress disorder (PTSD) and other stress-induced psychiatric disorders. This patent allowance strengthens Silo's intellectual property portfolio in Canada, complementing a recently granted European patent for the same invention. Silo holds an exclusive license from Columbia University for the Canadian patent, which grants it rights to develop, manufacture, and commercialize SPC-15 globally. The company intends to pursue the FDA's streamlined 505(b)(2) regulatory pathway for SPC-15, which could accelerate clinical development and reduce costs compared to traditional new drug applications.

Beyond the Canadian patent, Silo is advancing its pipeline with a focus on underserved conditions including chronic pain and central nervous system diseases. Its portfolio includes SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company collaborates with leading universities and laboratories, as detailed on its website, silopharma.com. The company's newsroom at https://ibn.fm/SILO provides the latest updates for investors. This development is a significant milestone for Silo as it progresses its lead candidate toward clinical trials, potentially offering a new treatment option for PTSD patients who currently have limited pharmacological choices.